KineMed: Business Development - Pathway-based Drug Discovery, Translational Medicine Development

8/14/08	Dr. Robert Stein, MD, PhD, Named CEO of KineMed
1/1/08	Repositioning Idle Drugs via Systematic Serendipity; Systems-based Approaches for Boosting Stalled Drugs
10/11/07	KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
8/28/07	KineMed to Collaborate with Merck KGaA to Validate New Applications for Drug Development Candidates; Technology to be Applied to Both Clinical- and Preclinical-Stage Compounds in Merck KGaA Pipeline
	more...

Partnering with KineMed

KineMed has numerous active partner collaborations in its Indications Discovery Program and its core Development Programs of:

Atherosclerosis
Diabetes
Fibrosis and Osteoarthritis
Neurogenesis and Neurodegeneration

KineMed's business strategy is to actively pursue strategic relationships for both Clinical Development Collaborations and Indications Discovery Collaborations as well as specific compound in-licensing opportunities. KineMed also interested in discussing joint-development collaborations around its core technology platform.